European EMA Grants Final Marketing Authorization for Fresenius Kabi's Adalimumab Biosimilar, Idacio
Biosimilar Enters the European Market
The European Medicines Agency (EMA) has completed the final marketing authorization for Idacio, the adalimumab biosimilar from Fresenius Kabi. This approval follows the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on January 31, 2019, and the official approval on April 2, 2019. It represents a significant milestone as it is Fresenius Kabi's first biosimilar pipeline to be commercialized. Idacio, a treatment for autoimmune diseases and a global bestseller, was developed using Humira as a reference medicine and has been recognized for its equivalent efficacy and safety in approximately 10 indications, including rheumatoid arthritis and psoriasis. The regulatory approval confirms that thorough quality comparison analyses, as well as non-clinical and clinical data, have fully demonstrated its high degree of similarity to the original drug.
Clinical Validation and Data for Demonstrating Equivalence
The regulatory approval of Idacio is based on data from the Phase 1 pharmacokinetic study (EMR200588-001) and the Phase 3 AURIEL-RA and AURIEL-Psoriasis trials. In the Phase 1 study, Idacio demonstrated bioequivalence, with key parameters such as maximum plasma concentration (Cmax) and area under the curve (AUC) falling within the statistical equivalence range of 80% to 125% compared to the reference drug. The subsequent Phase 3 AURIEL trials, conducted on patients with moderate to severe rheumatoid arthritis and psoriasis, evaluated efficacy, immunogenicity, and safety, demonstrating no significant differences compared to the reference drug. In particular, when compared to reference drugs marketed in the United States or Europe, the frequency of adverse events and the rate of hypersensitivity reactions were similar, completely alleviating concerns regarding safety.
Humira Patent Expiry and Intensifying Competition in the European Market
This approval comes at a time when the biosimilar competition in the European market is intensifying, following the expiry of Humira's substance patent in Europe in October 2018. At that time, four competing products, including Amgen's Amgevita, Sandoz's Hyrimoz, Samsung Bioepis and Biogen's Imraldi, and Mylan's Hulio, had already been launched in the European market, engaging in fierce competition for market share. Fresenius Kabi, as a late entrant, is leveraging its existing intravenous drug production infrastructure and global distribution network to secure market share. The company is also offering a simultaneous lineup of various formulations, including autoinjectors and pre-filled syringes, to enhance patient convenience and differentiate itself from competitors.
Price Competition and Reduced Healthcare Costs
The EMA's approval of Idacio is expected to put further downward pressure on the global adalimumab market, which was worth $19.7 billion annually. European countries are actively promoting price competition through the introduction of drug tendering systems, and the entry of Idacio could facilitate price reductions of 30% to 50% compared to the original drug. This will not only alleviate the financial burden on national healthcare systems but also significantly improve access to expensive biologics for patients who previously could not afford them. In the long term, it is expected to contribute to the creation of an environment in which patients can receive standard treatments for autoimmune diseases at a lower cost, further increasing prescription rates.
The European EMA's final approval of Idacio signifies Fresenius Kabi's full-scale entry into the Humira market, which had global sales of $19.7 billion in 2019. Based on the bioequivalence demonstrated in the Phase 1 study (EMR200588-001) and the safety demonstrated in the Phase 3 study (AURIEL-RA), immediate competition for market share with existing biosimilar leaders such as Amgevita and Hyrimoz is expected. From an investor's perspective, the key indicator is whether Fresenius Kabi can leverage its intravenous drug production facilities to lower costs and secure a 30% or more price advantage over the originator, enabling early market penetration. From a research and regulatory perspective, the continued emergence of follow-on biosimilars will serve as a catalyst for improving drug tendering systems and expanding long-term access to treatment for autoimmune disease patients in Europe. This diversification of the competitive landscape is expected to serve as a major benchmark case for global pharmaceutical companies' portfolio restructuring strategies following patent expirations.
Source: EMA (ema)